CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Genis is developing SIMECOS, a biocompatible drug aimed at treating osteoarthritis by resolving inflammation and promoting tissue regeneration. This innovative approach seeks to provide a safer and more effective alternative to current pain management therapies for millions affected by this condition.
Osteoarthritis (OA) is one of the leading causes of global disability, especially among the Elderly populations – approximately 10–12% of the adult population in the world has symptomatic OA.
Specifically, it affects more than 40 million people in Europe.
Currently there is no cure for OA – there are no current therapies available that can reverse or halt the progression of osteoarthritis. OA's control strategy mainly consists of palliative pain treatment as there are several medicines on the m…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
